Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial

被引：0

作者：

Waidmann, O. ^{[1
]}

Abou-Alfa, G. K. ^{[2
]}

Meyer, T. ^{[3
]}

Cheng, A-L ^{[4
]}

El-Khoueiry, A. B. ^{[5
]}

Rimassa, L. ^{[6
]}

Ryoo, B-Y ^{[7
]}

Cicin, I ^{[8
]}

Merle, P. ^{[9
]}

Chen, Y. H. ^{[10
]}

Park, J-W ^{[11
]}

Blanc, J-F ^{[12
]}

Bolondi, L. ^{[13
]}

Klumpen, H-J ^{[14
]}

Chan, S. L. ^{[15
]}

Dadduzio, V ^{[16
]}

Hessel, C. ^{[17
]}

Borgman-Hagey, A. E. ^{[17
]}

Schwab, G. ^{[17
]}

Kelley, R. K. ^{[18
]}

机构：

[1] Univ Liver & Canc Ctr Frankfurt, Frankfurt, Germany

[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[3] Royal Free Hosp, London, England

[4] Natl Taiwan Univ Hosp, Taipei, Taiwan

[5] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA

[6] Humanitas Canc Ctr, Humanitas Clin & Res Ctr, Rozzano, Italy

[7] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[8] Trakya Univ, Sch Med, Edirne, Turkey

[9] Groupement Hosp Lyon Nord, Lyon, France

[10] Liou Ying ChiMei Hosp, Dept Med Oncol, Tainan, Taiwan

[11] Natl Canc Ctr, Goyang, South Korea

[12] CHU, Hop Haut Leveque, Bordeaux, France

[13] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy

[14] Univ Amsterdam, Dept Med Oncol, Acad Med Ctr, Amsterdam, Netherlands

[15] Chinese Univ Hong Kong, State Key Lab Oncol South China, Hong Kong, Hong Kong, Peoples R China

[16] UOC, Ist Oncol Veneto, IRCCS, Padua, Italy

[17] Exelixis Inc, San Francisco, CA USA

[18] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V763

引用

页码：254 / 254

页数：1

共 50 条

[21] Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)
Rimassa, L.
Kelley, R. K.
Meyer, T.
Ryoo, B-Y.
Merle, P.
Park, J-W.
Blanc, J-F.
Lim, H. Y.
Tran, A.
Borgman-Hagey, A. E.
Clary, D. O.
Wang, E.
Cheng, A-L.
El-Khoueiry, A. B.
Abou-Alfa, G. K.
ANNALS OF ONCOLOGY, 2019, 30 : 257 - U138
[22] Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma
Cheng, A.
Kang, Y.
Chen, Z.
Tsao, C.
Qin, S.
Kim, J.
Burock, K.
Zou, J.
Voliotis, D.
Guan, Z. Z.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[23] Outcomes based on albumin-bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Chan, S. L.
Miksad, R.
Cicin, I.
Chen, Y.
Klumpen, H. J.
Kim, S.
Lin, Z. Z.
Youkstetter, J.
Sen, S.
Cheng, A-L.
El-Khoueiry, A. B.
Meyer, T.
Kelley, R. K.
Abou-Alfa, G. K.
ANNALS OF ONCOLOGY, 2019, 30
[24] Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Meyer, T.
Kelley, R. K.
Mangeshkar, M.
Cheng, A-L.
El-Khoueiry, A. B.
Abou-Alfa, G. K.
ANNALS OF ONCOLOGY, 2019, 30
[25] Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Yau, T.
Meyer, T.
Kelley, R. K.
Mangeshkar, M.
Cheng, A-L.
El-Khoueiry, A. B.
Abou-Alfa, G. K.
ANNALS OF ONCOLOGY, 2019, 30
[26] Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial
Bruix, J.
Merle, P.
Granito, A.
Huang, Y. -H.
Bodoky, G.
Yokosuka, O.
Rosmorduc, O.
Breder, V.
Gerolami, R.
Masi, G.
Paul, J. Ross
Qin, S.
Song, T.
Bronowicki, J. -P.
Ollivier-Hourmand, I.
Kudo, M.
LeBerre, M. -A.
Baumhauer, A.
Meinhardt, G.
Han, G.
ANNALS OF ONCOLOGY, 2016, 27 : 140 - +
[27] Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC)
Kelley, R. K.
El-Khoueiry, A. B.
Meyer, T.
Rimassa, L.
Merle, P.
Chan, S. L.
Tran, A.
Parnis, F.
Tam, V. C.
Cattan, S.
Markby, D. W.
Clary, D. O.
Cheng, A-L.
Abou-Alfa, G. K.
ANNALS OF ONCOLOGY, 2018, 29
[28] Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy.
Kelley, Robin Kate
Cheng, Ann-Lii
Braiteh, Fadi S.
Park, Joong-Won
Benzaghou, Fawzi
Milwee, Steven
Borgman, Anne
El-Khoueiry, Anthony B.
Kayali, Zeid K.
Zhu, Andrew X.
Rimassa, Lorenza
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[29] Outcomes based on plasma biomarkers for the Phase III CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma
Zekry, A.
Rimassa, L.
Kelley, R.
Meyer, T.
Ryoo, B.
Merle, P.
Park, J.
Blanc, J.
Lim, H.
Tran, A.
Borgman-Hagey, A.
Clary, D.
Wang, E.
Cheng, A.
El-Khoueiry, A.
Abou-Alfa, G.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 41 - 42
[30] Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
Cainap, Calin
Qin, Shukui
Huang, Wen-Tsung
Chung, Ik Joo
Pan, Hongming
Cheng, Ying
Kudo, Masatoshi
Kang, Yoon-Koo
Chen, Pei-Jer
Toh, Han-Chong
Gorbunova, Vera
Eskens, Ferry A. L. M.
Qian, Jiang
McKee, Mark D.
Ricker, Justin L.
Carlson, Dawn M.
El-Nowiem, Saied
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (02) : 172 - U77

← 1 2 3 4 5 →